Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
Oct 16, 2024
Contract Type
partnership
OxfordBiotechnologySoftwareData And AnalyticsHealth CareScience And EngineeringArtificial Intelligence
Description
Exscientia has achieved milestones for two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments. Both lead compounds have met the product profile requirements and have shown a high level of differentiation in early profiling, with the potential to produce best-in-class assets. Exscientia is eligible to receive additional pre-commercial milestone payments of over $300 million and commercial milestones of over $300 million, as well as tiered royalties on product sales.
Company Information
Company
Exscientia
Location
Oxford, Mississippi, United States
About
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.